Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LJPC-401 in Hereditary Hemochromatosis
NCT03395704Phase 2Completed
- Sponsor
- La Jolla Pharmaceutical Company
- Start
- Nov 2017
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 4
01
Overview
A Phase 2 trial of hepcidin in hereditary hemochromatosis (HH), sponsored by La Jolla Pharmaceutical Company. Started Nov 2017; status: completed.
02
Drugs
hepcidin
03
Conditions
hereditary hemochromatosis (HH)
Beyond the preview
Go deeper on NCT03395704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395704.